Antisense & RNAi Therapeutics Market - Global Forecast 2026-2032

The Antisense & RNAi Therapeutics Market is projected to reach USD 6.25 Billion in 2026. It is expected to continue growing at a CAGR of 15.76%, reaching USD 15.23 Billion by 2032.

Antisense and RNA interference (RNAi) therapeutics use nucleic-acid sequences to selectively modulate gene expression. Antisense medicines generally bind messenger RNA or related transcripts, while RNAi therapies use small interfering RNA to promote sequence-specific transcript degradation. Their clinical value is strongest where conventional medicines cannot readily address disease-driving genes, although delivery, durability, immune effects, and manufacturing complexity remain important considerations.

Delivery, Durability, and Precision Are Reshaping Development

The field is shifting from proof of genetic modulation toward dependable delivery to specific organs and tissues. Advances in chemical modification, conjugation, lipid-based systems, and other targeted delivery approaches are intended to improve cellular uptake while limiting off-target activity and immune stimulation. Longer dosing intervals, biomarker-guided development, and increasingly specialized treatment populations are also influencing clinical strategy, regulatory planning, and commercial access discussions.

Artificial Intelligence Strengthens Target Selection and Development Decisions

Artificial intelligence can support target discovery by integrating genomic, transcriptomic, clinical, and literature data to identify disease-linked pathways and prioritize candidate sequences. It can also assist with off-target assessment, chemical-design optimization, patient stratification, trial recruitment, and interpretation of response biomarkers. These applications do not remove the need for laboratory and clinical validation: data quality, model transparency, biological causality, privacy, and regulatory traceability remain central requirements.

Regional Landscape: Distinct Strengths Across Six Geographies

North America combines advanced biotechnology infrastructure, specialist clinical networks, and established regulatory experience in nucleic-acid medicines. Europe benefits from strong translational research and coordinated scientific capacity, while the European Union adds cross-border regulatory and health-technology considerations. Asia-Pacific is supported by expanding biopharmaceutical capabilities, substantial clinical populations, and growing investment in advanced modalities. Latin America is relevant for trial access and healthcare-system partnerships, with adoption shaped by reimbursement and specialist capacity. The Middle East is developing precision-medicine and innovation programs, particularly through major healthcare institutions. Africa offers important opportunities for inclusive research and future access planning, but infrastructure, diagnostics, financing, and supply continuity require sustained attention.

Group Insights: Policy Alignment and Manufacturing Capacity Matter

ASEAN economies present a diverse combination of emerging biopharmaceutical capability, clinical-trial potential, and varied regulatory systems. BRICS members contribute significant scientific, manufacturing, and patient-population resources, although policy environments and access conditions differ materially. The European Union emphasizes coordinated regulatory science alongside national reimbursement decisions. G7 countries provide major research, financing, and healthcare-system capabilities. GCC states are strengthening precision-health infrastructure and regional care networks. NATO members collectively include extensive biomedical research and public-health capacity, but their healthcare, procurement, and regulatory systems remain nationally determined.

Country Insights: Research Capability and Access Conditions Differ

The United States and Canada have strong translational ecosystems and specialist treatment capacity. The United Kingdom, Germany, France, Italy, and Spain combine advanced research and clinical infrastructure with distinct assessment and reimbursement pathways. Australia supports high-quality clinical research across a geographically dispersed system. Japan and South Korea have sophisticated pharmaceutical, regulatory, and hospital capabilities. China is expanding domestic innovation, clinical development, and manufacturing depth. India offers substantial scientific and production capacity alongside a large and diverse healthcare environment. Brazil and Mexico are important Latin American markets for specialist care and clinical research, with access influenced by regional disparities. Russia retains scientific and clinical capabilities, while regulatory and international collaboration conditions can affect development and availability.

Priorities for Leaders: Build Evidence, Delivery, and Access Readiness

Industry leaders should prioritize validated targets, tissue-specific delivery, and clinically meaningful biomarkers rather than treating sequence design alone as the primary differentiator. Development plans should integrate early assessment of immunogenicity, off-target effects, durability, manufacturing robustness, and long-term safety monitoring. Partnerships with diagnostic providers, specialist centers, patient organizations, and local healthcare institutions can improve recruitment and implementation. Leaders should also design region-specific regulatory and reimbursement strategies, strengthen supply-chain resilience, and establish responsible AI governance covering data provenance, validation, explainability, and human oversight.

Research Methodology: Evidence-Based Synthesis of the Therapeutic Landscape

This executive summary synthesizes established scientific and healthcare evidence on antisense and RNAi therapeutics, including peer-reviewed research, regulatory principles, clinical-development practices, and publicly documented regional health-system characteristics. The assessment compares modalities by mechanism, delivery considerations, development requirements, infrastructure, and access conditions. Regional, group, and country observations are presented qualitatively to avoid unsupported quantification. Conclusions should be refreshed as clinical evidence, regulatory expectations, manufacturing technologies, and healthcare policies evolve.

Conclusion: Sustainable Progress Depends on Translation and Access

Antisense and RNAi therapeutics offer a precise approach to modulating disease-relevant genes and are expanding the toolkit available for conditions with limited conventional options. Progress will depend on solving delivery and durability challenges, generating durable clinical evidence, and aligning manufacturing, regulation, diagnostics, and reimbursement. Organizations that combine rigorous biology with responsible data use, inclusive clinical development, and regionally informed access planning will be better positioned to translate nucleic-acid innovation into meaningful patient outcomes.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Antisense & RNAi Therapeutics Market, by Oligonucleotide Type

7.1. Introduction
7.2. Antisense Oligonucleotides
7.3. Interfering RNAi
7.3.1. Micro Interfering RNAs
7.3.2. Small Interfering RNAs

8. Antisense & RNAi Therapeutics Market, by Mode Of Administration

8.1. Introduction
8.2. Intrathecal
8.3. Intravenous
8.4. Oral
8.5. Subcutaneous
8.6. Topical

9. Antisense & RNAi Therapeutics Market, by Therapeutic Areas

9.1. Introduction
9.2. Cardiovascular
9.3. Immunology
9.4. Metabolic Disorders
9.5. Neurological Disorders
9.6. Oncology
9.7. Ophthalmology
9.8. Rare Diseases

10. Antisense & RNAi Therapeutics Market, by End User

10.1. Introduction
10.2. Contract Research Organizations
10.3. Pharmaceutical Companies
10.4. Research Laboratories

11. Antisense & RNAi Therapeutics Market, by Region

11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa

12. Antisense & RNAi Therapeutics Market, by Group

12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO

13. Antisense & RNAi Therapeutics Market, by Country

13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea

14. Competitive Landscape

14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025

15. Company Profiles

15.1. Acuitas Therapeutics Inc.
15.2. Alloy Therapeutics, Inc.
15.3. Alnylam Pharmaceuticals, Inc.
15.4. Arbutus Biopharma Corporation
15.5. Arrowhead Pharmaceuticals, Inc.
15.6. AstraZeneca plc
15.7. Bayer AG
15.8. Benitec Biopharma Limited
15.9. City Therapeutics
15.10. Danaher Corporation
15.11. Eli Lilly and Company
15.12. Evox Therapeutics Ltd
15.13. GenScript Biotech Corporation
15.14. GSK PLC
15.15. Ionis Pharmaceuticals, Inc.
15.16. Merck KGaA
15.17. Novo Nordisk A/S
15.18. Pfizer Inc.
15.19. Ribocure Pharmaceuticals AB
15.20. Sanofi S.A.
15.21. Shanghai Argo Biopharmaceutical Co., Ltd.
15.22. Silence Therapeutics plc
15.23. Stoke Therapeutics, Inc.
15.24. Suzhou Ribo Life Science Co., Ltd.
15.25. Wave Life Sciences Ltd

16. Key Experts

List of Figures

FIGURE 1. Global Antisense & RNAi Therapeutics Market, Years Considered for the Study
FIGURE 2. Global Antisense & RNAi Therapeutics Market, Research Design
FIGURE 3. Global Antisense & RNAi Therapeutics Market, Research Framework
FIGURE 4. Global Antisense & RNAi Therapeutics Market, Data Triangulation
FIGURE 5. Global Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2025 vs 2032 (%)
FIGURE 7. Global Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2025 vs 2032 (%)
FIGURE 11. Global Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Antisense & RNAi Therapeutics Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Antisense & RNAi Therapeutics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Antisense & RNAi Therapeutics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Antisense & RNAi Therapeutics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Antisense & RNAi Therapeutics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Antisense & RNAi Therapeutics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Antisense & RNAi Therapeutics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Antisense & RNAi Therapeutics Market Share, by Key Player, 2025

List of Tables

TABLE 1. Global Antisense & RNAi Therapeutics Market Segmentation & Coverage
TABLE 2. Global Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 3. Global Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 4. Global Antisense Oligonucleotides Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Antisense Oligonucleotides Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Antisense Oligonucleotides Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Interfering RNAi Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Interfering RNAi Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Interfering RNAi Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Micro Interfering RNAs Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Micro Interfering RNAs Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Micro Interfering RNAs Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Small Interfering RNAs Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Small Interfering RNAs Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Small Interfering RNAs Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 17. Global Intrathecal Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Intrathecal Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Intrathecal Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Topical Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Topical Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Topical Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 33. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Immunology Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Immunology Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Immunology Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Ophthalmology Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Ophthalmology Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Ophthalmology Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Rare Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Rare Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Rare Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 55. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Research Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Research Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Research Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Antisense & RNAi Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Antisense & RNAi Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 71. North America Antisense & RNAi Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. North America Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 73. North America Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 74. North America Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 75. North America Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 76. North America Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 77. Latin America Antisense & RNAi Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Latin America Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 79. Latin America Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 80. Latin America Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 81. Latin America Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 82. Latin America Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 83. Europe Antisense & RNAi Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Europe Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 85. Europe Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 86. Europe Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 87. Europe Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 88. Europe Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. Middle East Antisense & RNAi Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Middle East Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 91. Middle East Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 92. Middle East Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 93. Middle East Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 94. Middle East Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 95. Africa Antisense & RNAi Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Africa Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 97. Africa Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 98. Africa Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 99. Africa Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 100. Africa Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 101. Global Antisense & RNAi Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. ASEAN Antisense & RNAi Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. ASEAN Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 104. ASEAN Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 105. ASEAN Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 106. ASEAN Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 107. ASEAN Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. GCC Antisense & RNAi Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. GCC Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 110. GCC Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 111. GCC Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 112. GCC Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 113. GCC Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. European Union Antisense & RNAi Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. European Union Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 116. European Union Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 117. European Union Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 118. European Union Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 119. European Union Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. BRICS Antisense & RNAi Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. BRICS Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 122. BRICS Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 123. BRICS Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 124. BRICS Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 125. BRICS Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 126. G7 Antisense & RNAi Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. G7 Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 128. G7 Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 129. G7 Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 130. G7 Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 131. G7 Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 132. NATO Antisense & RNAi Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. NATO Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 134. NATO Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 135. NATO Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 136. NATO Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 137. NATO Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. Global Antisense & RNAi Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 139. United States Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 140. United States Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 141. United States Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 142. United States Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 143. United States Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 144. United States Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. Canada Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 146. Canada Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 147. Canada Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 148. Canada Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 149. Canada Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 150. Canada Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. Mexico Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 152. Mexico Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 153. Mexico Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 154. Mexico Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 155. Mexico Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 156. Mexico Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. Brazil Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 158. Brazil Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 159. Brazil Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 160. Brazil Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 161. Brazil Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 162. Brazil Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. United Kingdom Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 164. United Kingdom Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 165. United Kingdom Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 166. United Kingdom Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 167. United Kingdom Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 168. United Kingdom Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. Germany Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 170. Germany Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 171. Germany Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 172. Germany Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 173. Germany Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 174. Germany Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. France Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 176. France Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 177. France Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 178. France Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 179. France Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 180. France Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. Russia Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 182. Russia Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 183. Russia Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 184. Russia Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 185. Russia Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 186. Russia Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. Italy Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 188. Italy Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 189. Italy Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 190. Italy Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 191. Italy Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 192. Italy Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. Spain Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 194. Spain Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 195. Spain Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 196. Spain Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 197. Spain Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 198. Spain Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. China Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 200. China Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 201. China Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 202. China Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 203. China Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 204. China Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. India Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 206. India Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 207. India Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 208. India Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 209. India Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 210. India Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. Japan Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 212. Japan Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 213. Japan Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 214. Japan Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 215. Japan Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 216. Japan Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. Australia Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 218. Australia Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 219. Australia Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 220. Australia Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 221. Australia Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 222. Australia Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 223. South Korea Antisense & RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 224. South Korea Antisense & RNAi Therapeutics Market Size, by Oligonucleotide Type, 2017-2032 (USD Million)
TABLE 225. South Korea Antisense & RNAi Therapeutics Market Size, by Interfering RNAi, 2017-2032 (USD Million)
TABLE 226. South Korea Antisense & RNAi Therapeutics Market Size, by Mode Of Administration, 2017-2032 (USD Million)
TABLE 227. South Korea Antisense & RNAi Therapeutics Market Size, by Therapeutic Areas, 2017-2032 (USD Million)
TABLE 228. South Korea Antisense & RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 229. Global Antisense & RNAi Therapeutics Market Share, by Key Player, 2025
TABLE 230. Global Antisense & RNAi Therapeutics Market, Key Experts

Companies Mentioned

Acuitas Therapeutics Inc.
Alloy Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc.
Arbutus Biopharma Corporation
Arrowhead Pharmaceuticals, Inc.
AstraZeneca plc
Bayer AG
Benitec Biopharma Limited
City Therapeutics
Danaher Corporation
Eli Lilly and Company
Evox Therapeutics Ltd
GenScript Biotech Corporation
GSK PLC
Ionis Pharmaceuticals, Inc.
Merck KGaA
Novo Nordisk A/S
Pfizer Inc.
Ribocure Pharmaceuticals AB
Sanofi S.A.
Shanghai Argo Biopharmaceutical Co., Ltd.
Silence Therapeutics plc
Stoke Therapeutics, Inc.
Suzhou Ribo Life Science Co., Ltd.
Wave Life Sciences Ltd

Table Information

Report Attribute	Details
No. of Pages	181
Published	September 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 6.25 Billion
Forecasted Market Value ( USD ) by 2032	$ 15.23 Billion
Compound Annual Growth Rate	15.7%
Regions Covered	Global
No. of Companies Mentioned	25

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3162EUR$3,545USD£2,719GBP €3514EUR$3,939USD£3,021GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4784EUR$5,363USD£4,113GBP €5316EUR$5,959USD£4,570GBP

Delivery, Durability, and Precision Are Reshaping Development

Artificial Intelligence Strengthens Target Selection and Development Decisions

Regional Landscape: Distinct Strengths Across Six Geographies

Group Insights: Policy Alignment and Manufacturing Capacity Matter

Country Insights: Research Capability and Access Conditions Differ

Priorities for Leaders: Build Evidence, Delivery, and Access Readiness

Research Methodology: Evidence-Based Synthesis of the Therapeutic Landscape

Conclusion: Sustainable Progress Depends on Translation and Access

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Antisense and RNAi Therapeutics - Global Strategic Business Report

Antisense & RNAi Therapeutics Market Size, Share, Trends and Forecast by Technology, Route of Administration, Application, and Region, 2026-2034

Antisense & RNAi Therapeutics Market Report 2026

Antisense & Rnai Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis

Antisense and RNAi Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)